Chonluten
Also known as: Chonluten tripeptide, Khavinson Peptide (bronchial)
Ultrashort signaling peptide (tripeptide); Khavinson Peptide
What it is
Chonluten is a short peptide studied in Russian research for lung protection and immune modulation, particularly in the context of aging and respiratory inflammation. Evidence is limited to cell culture and early animal studies. No FDA-approved use; limited independent research outside of the original research group.
The scientific side
Chonluten is a tripeptide originally isolated from bronchial epithelial cells and characterized as organ-specific. In vitro studies show it modulates inflammatory and proliferative processes: it increases tyrosine phosphorylation of mitogen-activated cytoplasmic kinases, inhibits TNF production in LPS-stimulated monocytes (linked to a documented mechanism of TNF tolerance), suppresses pro-inflammatory IL-6 cytokine expression in terminally differentiated macrophages, and reduces monocyte adhesion to LPS-activated endothelial cells. As an ultrashort peptide (2–7 amino acid residues), it is proposed to act as a signaling molecule regulating gene expression and protein synthesis, and may be transported into cells via POT (PEPT1, PEPT2, PHT1, PHT2) and/or LAT family transporters, a mechanism thought to underlie tissue specificity and geroprotective action.
Class: Ultrashort signaling peptide (tripeptide); Khavinson Peptide
Administration & storage
- Administration
- In vitro incubation (cell culture medium) (PMID: 35408963)
- Storage
- No storage conditions for Chonluten are described in the reviewed abstracts.
- Cautions
- No human pharmacokinetic or safety data for Chonluten are reported in the reviewed abstracts — clinical safety profile is unknown.,All efficacy data derive from in vitro cell culture studies; translation to human use has not been established in the reviewed literature.,The reviewed literature does not address formulation purity, sterility standards, or acceptable excipients for any route of administration.,Sterile technique is universally required for any injectable preparation; failure to maintain sterility poses infection risk regardless of the compound used.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Anti-inflammatory modulation in monocytes/macrophages (in vitro) In vitro only
- Chonluten tripeptide inhibited TNF production in LPS-stimulated THP-1 monocytes, suppressed IL-6 expression in PMA-differentiated macrophages stimulated by LPS, and reduced monocyte adhesion to LPS-activated HUVECs. All five Khavinson peptides increased tyrosine phosphorylation of mitogen-activated cytoplasmic kinases. PMID 35408963 Avolio F et al. Int J Mol Sci. 2022.
- Potential bronchoprotective and immunomodulatory effects relevant to respiratory infection (proposed) In vitro only
- A review proposed that peptides with immuno- and bronchoprotective effects on lung cells, including those normalizing cytokine synthesis and exerting anti-inflammatory effects, may have relevance to COVID-19 pathology. Chonluten is noted as a bronchial epithelial-derived peptide in the broader Khavinson peptide family PMID 32987757 Khavinson V et al. Molecules. 2020.
- Geroprotection and regulation of neuroimmunoendocrine system (proposed mechanistic basis) In vitro only
- Review concludes that di- and tripeptides can be transported into cells of various tissues by POT and LAT transporters; this mechanism is proposed to underlie tissue specificity, geroprotective action, and effectiveness in neuroimmunoendocrine system disorders. No Chonluten-specific data presented. PMID 35887081 Khavinson V et al. Int J Mol Sci. 2022.
Safety signals
- The reviewed abstracts state that peptides in general 'have virtually no side effects' given their physiological mechanism of action at low concentrations, but no specific safety data or adverse event data for Chonluten are presented. PMID 32987757
Protocol
20 mcg sublingual, once daily. Cycle: 10 days.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| In vitro incubation with THP-1 cell cultures | Concentrations described as 'known for being effective on recipient cells in culture' — specific numeric concentration not stated in abstract | Not specified in abstract | in_vitro | Research PMID 35408963 |
| sublingual | 20 mcg | once daily · 10 days | biohackers and longevity-focused adults interested in lung/respiratory health | [Community] |
| sublingual | 20 mcg | once daily · 20 days | adults with chronic respiratory conditions or heavy smokers seeking lung support | [Community] |
| sublingual | 20 mcg | once daily · 10 days, repeated twice per year | biohackers running stacked bioregulator peptide protocols for anti-aging / longevity | [Community] |
| sublingual | 20 mcg | once daily · 10 days, repeated 3x per year | older adults (50+) or those with ongoing respiratory vulnerability (e.g. post-illness, pollution exposure) | [Community] |
All studies (3)
- PMID 32987757 In vitro only
Potential bronchoprotective and immunomodulatory effects relevant to respiratory infection (proposed - PMID 35408963 In vitro only
Anti-inflammatory modulation in monocytes/macrophages (in vitro) - PMID 35887081 In vitro only
Geroprotection and regulation of neuroimmunoendocrine system (proposed mechanistic basis)
Frequently asked
What is Chonluten and where does it come from?
Chonluten is a tripeptide originally isolated from bronchial epithelial cells. It belongs to a class of organ-specific signaling peptides characterized by Professor Khavinson from 1973 onwards, sometimes called 'Khavinson Peptides.'
What has research shown Chonluten does?
Published in vitro research shows that Chonluten inhibited TNF production in LPS-stimulated monocytes (linked to TNF tolerance mechanisms), suppressed IL-6 expression in macrophages stimulated by LPS, and reduced monocyte adhesion to activated endothelial cells. It also increased tyrosine phosphorylation of mitogen-activated cytoplasmic kinases in THP-1 cells. All current evidence is from cell culture studies; no human clinical trials are reported in the reviewed literature.
Has Chonluten been studied for COVID-19 or lung protection?
A 2020 review discussed the broader class of Khavinson peptides — including bronchial epithelial-derived peptides — as having potential immuno- and bronchoprotective effects relevant to COVID-19 pathology. However, the review did not present clinical trial data specific to Chonluten, and no clinical efficacy for COVID-19 has been established in the reviewed literature.
How does Chonluten get into cells?
A review on ultrashort peptide transport proposes that tripeptides like Chonluten may enter cells via POT family transporters (PEPT1, PEPT2, PHT1, PHT2) and possibly LAT family transporters. This mechanism is suggested to underlie the tissue specificity and proposed geroprotective properties of such peptides. This is a proposed mechanistic model and has not been specifically confirmed for Chonluten in the reviewed abstracts.
What dose of Chonluten should I take?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: the only published data are from in vitro cell culture experiments using concentrations described as 'effective on recipient cells in culture' — no specific numeric dose or human dosing protocol is reported in the reviewed literature.
Can I stack Chonluten with other peptides?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: Chonluten has only been studied in vitro as one of five Khavinson peptides; no combination (stacking) protocols involving Chonluten are reported in the reviewed literature.
Is Chonluten approved by the FDA or legal to use?
The reviewed scientific literature does not state the current regulatory status of Chonluten with the US FDA, Health Canada, or WADA. I don't have reliable study data on that specific question. I won't guess — please consult a licensed provider or peer-reviewed literature directly.
Where can I buy Chonluten?
I don't recommend vendors or sources. Please consult a licensed provider.
Is Chonluten safe? Are there side effects?
The reviewed literature contains no human safety data or adverse event reports for Chonluten. One review noted that peptides in this class generally 'have virtually no side effects' given their physiological mechanism of action at low concentrations, but this is a general statement and no specific safety studies for Chonluten are available in the reviewed abstracts. Please consult a licensed healthcare provider before use.
Can Chonluten treat my respiratory condition?
I can't suggest treatments for medical conditions. Please speak with a licensed healthcare provider. The only available evidence for Chonluten is from in vitro cell culture studies; no human clinical trials establishing therapeutic efficacy for any condition are reported in the reviewed literature.